JPMorgan reiterates Overweight on Salesforce stock, $265 target

JPMorgan reiterated an Overweight rating and $265 price target on Salesforce following its investor day, while management reaffirmed its fiscal 2030 revenue target of more than $63 billion and expects organic-growth reacceleration in the second half of fiscal 2027. Salesforce highlighted AI-led monetization through seat expansion and consumption pricing, supported by new platform capabilities including AIforce and Koa. Multiple analysts maintained or raised bullish targets, ranging from $275 to $300, citing stronger AI product momentum, while Salesforce reported 77% gross margins and trades at a 23.24x P/E with a 0.38 PEG ratio.

Analysis

The investable issue is not product visibility but whether AI converts from bundled retention tooling into incremental, high-margin spend. A hybrid seat/consumption model can improve net retention and reduce displacement risk from NOW, MSFT and ORCL, but it also makes revenue recognition and customer budgeting less predictable; investors should expect a lag between pilot enthusiasm and material consumption revenue. The key proof point over the next 1-3 quarters is accelerating remaining performance obligations and subscription/consumption growth without a corresponding deterioration in sales-and-marketing efficiency or operating-margin trajectory.

A higher-rate backdrop is unfavorable for a long-duration software rerating, particularly when sell-side targets are clustered and the narrative is already consensus-positive. CRM can still outperform if its revenue re-acceleration becomes measurable, but absent that evidence the likely outcome is multiple compression offsetting modest estimate upgrades. NVDA benefits indirectly only if enterprise inference deployments translate into sustained workloads; CRM's model announcements alone are insufficient evidence of incremental GPU demand.

The contrarian view is that AI interface flexibility may commoditize the application layer rather than deepen CRM's moat: customers could retain Salesforce as a data repository while routeing agent workflows through Microsoft, ServiceNow, or custom models. That risk rises if consumption pricing is used primarily as a discounting tool to protect seats. Falsification for the bearish relative view would be two consecutive quarters of accelerating net-new bookings/RPO, stable or expanding operating margin, and explicit evidence that AI revenue is additive rather than cannibalizing existing licenses.

Key Decisions for Investors

• No immediate outright CRM add on analyst commentary alone. Establish a 1-3 month watch trigger: go long CRM only after the next earnings release shows both accelerating RPO/bookings and no downward revision to forward operating-margin or free-cash-flow expectations; size for a 10-15% downside stop if those metrics fail to confirm.
• For AI-software exposure, prefer a 6-12 month pair trade long CRM / short NOW in equal beta-adjusted dollars only if CRM demonstrates incremental consumption growth. The thesis is valuation catch-up from CRM monetizing its installed data base; exit if NOW sustains superior subscription growth by more than 500 bps or CRM guides to increased discounting.
• Hedge any CRM long with QQQ puts or a short IGV overlay through the next Fed and earnings cycle. The principal near-term risk is duration-driven multiple compression rather than company-specific execution, and the hedge should be reduced only after rate volatility and CRM guidance risk clear.
• Do not extrapolate CRM platform announcements into NVDA or SMCI revenue. Revisit a long NVDA catalyst trade only if enterprise disclosures identify incremental inference infrastructure commitments, utilization, or partner backlog; model launches without disclosed workload economics are not a sufficient demand signal.